Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Beijing Aosaikang Pharmaceutical Co., Ltd. (002755.SZ)
CNY14.47
-0.12 (-0.82%)
CN SHZ Healthcare Drug Manufacturers - Specialty & Generic
Address
Jiangning Science Park 211112
Nanjing, CN
Nanjing, CN
CEO
Jingfei Ma
Website
ask-pharm.com
IPO
2015-05-15
ISIN CNE100001X92
Description
Operating within China, Beijing Aosaikang Pharmaceutical Co., Ltd. specializes in the research, development, production, and sale of pharmaceuticals, fine chemicals, and health products. Its diverse offerings include proton pump inhibitor injections, oncology medications, and active pharmaceutical ingredients (APIs), which are applied across key therapeutic areas like digestive disorders, cancer treatment, and infectious diseases. The company was founded in 2003 and is headquartered in Nanjing, China.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY14.47
-0.12 (-0.82%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
18M
Beta
0.13
Float Shares
655.71M
Free Float %
70.6%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.62% | -16.37% | -10.18% | -5.15% | -17.41% | -10.84% | -11.76% | +35.57% | +8.66% | -23.13% | +129.29% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
14.47
DCF (Unlevered)
2.19
-84.8%
DCF (Levered)
4.91
-66.1%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
9.19
Safe zone
Piotroski F-Score
5 / 9
Average
MOAT Score
6 / 10
Developing
Composite Rating
B+
Overall Score
3 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
4 / 5
High
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+0.1% Q1'26: -5.3% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+47.1% ★ Q1'26: +50.0% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+28.8% ★ Q1'26: +3.9% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+14.3% ★ Q1'26: +23.7% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+26.0% ★ Q1'26: +46.5% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.4% Q1'26: +2.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.08× ★ Q1'26: 0.01× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
3.09B
est: 357.00M (+766.2%)
|
3.40B
est: 422.00M (+706.8%)
|
3.93B
est: 498.00M (+689.5%)
|
3.78B
est: 357.00M (+959.6%)
|
3.11B
est: 422.00M (+636.2%)
|
1.87B
est: 498.00M (+276.0%)
|
1.44B
est: 1.46B (-0.9%)
|
1.78B
est: 1.79B (-0.9%)
|
1.78B
est: 2.04B (-12.9%)
|
2.28B
2.28B – 2.28B
+11.6% YoY
|
2.66B
2.66B – 2.66B
+16.7% YoY
|
3.01B
3.01B – 3.01B
+13.1% YoY
|
| EBITDA |
735.87M
est: 12.75M (+5,671.1%)
|
727.90M
est: 15.07M (+4,729.3%)
|
798.19M
est: 17.79M (+4,387.4%)
|
825.17M
est: 12.75M (+6,371.4%)
|
401.33M
est: 15.07M (+2,562.6%)
|
-224.03M
est: 17.79M (-1,359.5%)
|
-208.79M
est: 52.00M (-501.5%)
|
169.84M
est: 63.09M (+169.2%)
|
383.21M
est: 71.82M (+433.6%)
|
80.12M
80.12M – 80.12M
+11.6% YoY
|
93.48M
93.48M – 93.48M
+16.7% YoY
|
105.68M
105.68M – 105.68M
+13.1% YoY
|
| EBIT |
711.53M
est: -1.57M (+45,480.6%)
|
655.89M
est: -1.85M (+35,489.1%)
|
715.04M
est: -2.19M (+32,792.4%)
|
732.55M
est: -1.57M (+46,821.7%)
|
309.73M
est: -1.85M (+16,811.6%)
|
-313.20M
est: -2.19M (-14,220.0%)
|
-290.49M
est: -6.39M (-4,442.7%)
|
94.55M
est: -26.14M (+461.7%)
|
253.99M
est: -29.75M (+953.7%)
|
-33.19M
-33.19M – -33.19M
-11.6% YoY
|
-38.73M
-38.73M – -38.73M
-16.7% YoY
|
-43.78M
-43.78M – -43.78M
-13.1% YoY
|
| Net Income |
629.98M
est: 155.31M (+305.6%)
|
607.54M
est: 183.04M (+231.9%)
|
670.07M
est: 221.86M (+202.0%)
|
721.63M
est: 155.31M (+364.6%)
|
379.91M
est: 183.04M (+107.6%)
|
-225.83M
est: 221.86M (-201.8%)
|
-148.53M
est: -273.44M (+45.7%)
|
160.29M
est: 198.74M (-19.3%)
|
236.60M
est: 283.92M (-16.7%)
|
425.88M
425.88M – 425.88M
+50.0% YoY
|
558.38M
558.38M – 558.38M
+31.1% YoY
|
671.95M
671.95M – 671.95M
+20.3% YoY
|
| SGA |
1.94B
est: 240.85M (+703.4%)
|
2.21B
est: 284.70M (+677.3%)
|
2.58B
est: 335.98M (+668.7%)
|
2.44B
est: 240.85M (+912.8%)
|
2.16B
est: 284.70M (+658.3%)
|
1.33B
est: 335.98M (+296.9%)
|
973.24M
est: 982.29M (-0.9%)
|
1.15B
est: 1.17B (-1.9%)
|
962.82M
est: 1.34B (-27.9%)
|
1.49B
1.49B – 1.49B
+11.6% YoY
|
1.74B
1.74B – 1.74B
+16.7% YoY
|
1.97B
1.97B – 1.97B
+13.1% YoY
|
| EPS |
0.03
est: 0.16 (-82.2%)
|
0.80
est: 0.19 (+312.1%)
|
0.89
est: 0.24 (+278.3%)
|
0.78
est: 0.16 (+373.6%)
|
0.41
est: 0.19 (+111.2%)
|
-0.24
est: 0.24 (-203.4%)
|
-0.16
est: -0.29 (+44.8%)
|
0.17
est: 0.21 (-19.0%)
|
0.25
est: 0.30 (-16.7%)
|
0.45
0.45 – 0.45
+50.0% YoY
|
0.59
0.59 – 0.59
+31.1% YoY
|
0.71
0.71 – 0.71
+20.3% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-28 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-27 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-26 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-25 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-22 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-21 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-20 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-19 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-18 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-15 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-14 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-13 | B+ | 3/5 | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-12 | B+ | 3/5 | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-11 | B | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-08 | B | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-07 | B | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-06 | B | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 |
| 2026-04-30 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-29 | B | 3/5 | 3/5 | 3/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-28 | B | 3/5 | 3/5 | 3/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-27 | B | 3/5 | 3/5 | 3/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-24 | B- | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-23 | B- | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-22 | B- | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | B- | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | B- | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | B- | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | B- | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
345.74M
OE per share TTM
0.37
Owner's Yield
2.53%
Maintenance CapEx ratio
209.37%
Maint CapEx / Avg PPE
22.2%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 18 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Emerging Markets Equity Factor ETF EMGF | 0.02% | 286.6K | 0.26% |
| 2 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.00% | 536.4K | 0.06% |
| 3 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 19.1K | 0.48% |
| 4 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 43.1K | 0.26% |
| 5 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 2.13M | 0.06% |
| 6 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 69.8K | 0.29% |
| 7 | Vanguard ESG International Stock ETF VSGX | 0.00% | 19.5K | 0.10% |
| 8 | Vanguard Total International Stock ETF VXUS | 0.00% | 1.85M | 0.05% |
| 9 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 13.8K | 0.39% |
| 10 | Vanguard FTSE Global All Cap ex Canada Index ETF VXC.TO | 0.00% | 3.4K | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
259.4K
Shares Outstanding
928.16M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jingfei Ma | GM & Director | — | male |
| Tao Han | CFO & Head of Accounting Department | — | male |
| Xiangfeng Chen | Deputy GM & Non-Independent Director | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 002755.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
